The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease
Open accessAbstract
BACKGROUND: The risk of Parkinson disease (PD) and its rate of progression may decline with increasing concentration of blood urate, a major antioxidant. OBJECTIVE: To determine whether serum and cerebrospinal fluid concentrations of urate predict clinical progression in patients with PD. DESIGN, SETTING, AND PARTICIPANTS: Eight hundred subjects with early PD enrolled in the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) trial. The pretreatment urate concentration was measured in serum for 774 subjects and in cerebrospinal fluid for 713 subjects. MAIN OUTCOME MEASURES: Treatment-, age-, and sex-adjusted hazard ratios (HRs) for clinical disability requiring levodopa therapy, the prespecified primary end point of the original DATATOP trial. RESULTS: The HR of progressing to the primary end point decreased with increasing serum urate concentrations (HR for highest vs lowest quintile = 0.64; 95% confidence interval [CI], 0.44-0.94; HR for a 1-SD increase = 0.82; 95% CI, 0.73-0.93). In analyses stratified by alpha-tocopherol treatment (2000 IU/d), a decrease in the HR for the primary end point was seen only among subjects not treated with alpha-tocopherol (HR for a 1-SD increase = 0.75; 95% CI, 0.62-0.89; vs HR for those treated = 0.90; 95% CI, 0.75-1.08). Results were similar for the rate of change in the Unified Parkinson's Disease Rating Scale score. Cerebrospinal fluid urate concentration was also inversely related to both the primary end point (HR for highest vs lowest quintile = 0.65; 95% CI, 0.44-0.96; HR for a 1-SD increase = 0.89; 95% CI, 0.79-1.02) and the rate of change in the Unified Parkinson's Disease Rating Scale score. As with serum urate concentration, these associations were present only among subjects not treated with alpha-tocopherol. CONCLUSIONS: Higher serum and cerebrospinal fluid urate concentrations at baseline were associated with slower rates of clinical decline. The findings strengthen the link between urate concentration and PD and the rationale for considering central nervous system urate concentration elevation as a potential strategy to slow PD progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxidative stress: oxidants and antioxidants
Sies, H. (1997) · Experimental Physiology · doi:10.1113/expphysiol.1997.sp004024 · Cited by 4,566
Ames, B. N., Cathcart, R., Schwiers, E., & Hochstein, P. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.11.6858 · Cited by 2,909
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
MOLECULAR PATHOPHYSIOLOGY OF PARKINSON'S DISEASE
Moore, D. J., West, A. B., Dawson, V. L., & Dawson, T. M. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135718 · Cited by 1,280
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
Mitochondria take center stage in aging and neurodegeneration
Beal, M. F. (2005) · Annals of Neurology · doi:10.1002/ana.20624 · Cited by 957
Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 917
γ-Tocopherol, the major form of vitamin E in the US diet, deserves more attention
Jiang, Q., Christen, S., Shigenaga, M. K., & Ames, B. N. (2001) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/74.6.714 · Cited by 776
Bowry, V. W., & Stocker, R. (1993) · Journal of the American Chemical Society · doi:10.1021/ja00067a019 · Cited by 713
Uric Acid Is a Risk Factor for Myocardial Infarction and Stroke: The Rotterdam Study
Bos, M. J., Koudstaal, P. J., Hofman, A., Witteman, J. C. M., & Breteler, M. M. B. (2006) · Stroke · doi:10.1161/01.str.0000221716.55088.d4 · Cited by 615
Cited by
The epidemiology of Parkinson's disease: risk factors and prevention
Ascherio, A., & Schwarzschild, M. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30230-7 · Cited by 1,825
Self-citationEpidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199
Parkinson’s Disease in Women and Men: What’s the Difference?
Cerri, S., Mus, L., & Blandini, F. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191683 · Cited by 800
Parkinson disease: from pathology to molecular disease mechanisms
Dexter, D. T., & Jenner, P. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.01.018 · Cited by 707
The Molecular Physiology of Uric Acid Homeostasis
Mandal, A. K., & Mount, D. B. (2015) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170343 · Cited by 550
Metadata
- Authors
- Ascherio, A.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2009-12-01
- Volume
- 66
- Issue
- 12
- Pages
- 1460
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2142614156
- Cited by
- 354
- References
- 53
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease. https://app.cochat.ai/papers/10.1001/archneurol.2009.247
- The paper
- Ascherio, A. (2009). Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease. Archives of Neurology. https://doi.org/10.1001/archneurol.2009.247
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.